Leadership & Pay ·
On July 10, 2026, Oncotelic Therapeutics, Inc. approved the issuance of 17,796 restricted stock units (RSUs) to…
OTLCOncotelic Therapeutics, Inc.
On July 10, 2026, Oncotelic Therapeutics, Inc. approved the issuance of 17,796 restricted stock units (RSUs) to directors, officers, employees, and advisors. Each RSU entitles the holder to one share of Series A Convertible Preferred Stock, which is convertible into 1,000 shares of common stock. Vesting is contingent upon the company's common stock being uplisted to a national stock exchange by June 30, 2027, and the recipient remaining in service for six months post-uplisting. Key recipients include CEO Vuong Trieu, Ph.D., who was granted 2,000 RSUs. Oncotelic Therapeutics, Inc. is a biotechnology company.